Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Licenses microRNA Sequences from Max Planck for Dx Development

NEW YORK (GenomeWeb News) - Rosetta Genomics has licensed from the Max Planck Society rights to patents covering “potentially hundreds” of human microRNA sequences for use in diagnostic applications, the company said.
 
Rosetta said it will add the sequences to its microRNA database, where they will provide the company with additional biomarker candidates for its diagnostic-development programs.
 
Under the terms of the agreement, Rosetta will be able to use the sequences in research and development programs targeting new microRNA-based diagnostic tools for a variety of diseases.
 
The company will pay an initiation fee as well as maintenance fees and royalties to the Max Planck Society. Additional financial details were not disclosed.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.